from Limes Schlosskliniken AG (isin : DE000A0JDBC7)
EQS-Adhoc: Limes Schlosskliniken AG: Preliminary group result 2023 (unaudited) / forecast 2024
EQS-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Annual Results/Forecast
Limes Schlosskliniken AG: Preliminary group result 2023 (unaudited) / forecast 2024
06-Feb-2024 / 14:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP-Adhoc: Limes Schlosskliniken AG:
Preliminary group result 2023 (unaudited) / forecast 2024
- Total revenue EUR 37.4m + 26 %
- Patient days 46,641 + 26 %
- Gross earnings (EBITDA) 7.4 Mio. EUR - 15 %
- Operating result (EBIT) 4.7 Mio. EUR - 22 %
- Consolidated net income for the period 3,395 kEUR - 30 %
- Earnings after minorities and after taxes (EAT) EUR 3m - 30 %
- 60% of earnings (EBITDA) were generated in the second half of the year
- Lindlar clinic site: The owner will complete the property by early 2025 and hand it over to LIMES as operator
- Forecast 2024: Strong first half-year expected, double-digit growth at all clinic locations, total revenue EUR 44 m + 18 %; Commissioning of the new clinic location Abtsee in Q III; gross earnings (EBITDA) EUR 9.7 m (+ 31 %) incl. Start-up costs Abtsee
Cologne, February, 06, 2024: The LIMES Group continued to develop dynamically in 2023. The new location in Liechtenstein has been integrated and is performing significantly better than planned. Patient occupancy was higher at all locations in the second half of the year. After higher costs had to be covered in the first half of 2023 due to inflation, these were largely compensated by delayed price adjustments in the second half of the year.
For the current year 2024, we expect sales revenue of around EUR 44 million excluding new acquisitions and gross earnings (EBITDA) of EUR 9.7 million including the start-up losses of the new Abtsee site near Salzburg.
Kurzprofil: Die LIMES Schlosskliniken Gruppe betreibt hochwertige Privatkliniken für Stressfolgeerkrankung, Mentale und Seelische Störung, wie z. B. Despressionen, Affektive Störungen und akute Burnout Zustände. Das Angebot richtet sich an Privatpatienten, Beihilfeberechtigte und Selbstzahler. Die LIMES Schlosskliniken Gruppe stehen für den besonderen Ansatz einer beziehungsorientierten Medizin in der Behandlung von Menschen mit seelischen Erkrankungen. Dabei wird den Patienten, neben medizinischer Spitzenqualität, eine einzigartige, geschützte und heilsame Umgebung geboten, in der sie ganzheitlich genesen können. Weitere Informationen sind unter www.limes-schlosskliniken.de abrufbar.
Ihr Ansprechpartner bei Rückfragen:
LIMES Schlosskliniken AG, Petra Kaes, Investor Relations
Kaiser-Wilhelm-Ring 26, 50672 Köln
Tel.: 0221 669 615 10, p.kaes@limes.care, www.limes-schlosskliniken.de
Sprache: Deutsch
Unternehmen: LIMES Schlosskliniken AG, Kaiser-Wilhelm-Ring 26, 50672 Köln, Deutschland
Telefon: 49 221 669 615 10
Email: p.kaes@limes.care
Internet: www.limes-schlosskliniken.de
ISIN: DE000A0JDBC7
WKN: AOJDBC
Börsen: Düsseldorf Freiverkehr, Primärmarkt, XETRA
Ende der Mitteilung
End of Inside Information
06-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Limes Schlosskliniken AG |
| Kaiser-Wilhelm-Ring 26 | |
| 50672 Köln | |
| Germany | |
| ISIN: | DE000A0JDBC7 |
| WKN: | A0JDBC |
| Listed: | Regulated Unofficial Market in Dusseldorf |
| EQS News ID: | 1831535 |
| End of Announcement | EQS News Service |
1831535 06-Feb-2024 CET/CEST